Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 10, 2009, Pages 1113-1120

  Wong, Vincent Wai Sun ^a   Wong, Grace Lai Hung ^a   Chim, Angel Mei Ling ^a   Choi, Paul Cheung Lung ^a   Chan, Anthony Wing Hung ^a   Tsang, Steven Woon Choy ^b   Hui, Alex Yui ^a   Chan, Hoi Yun ^a   Sung, Joseph Jao Yiu ^a   Chan, Henry Lik Yuen ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b TSEUNG KWAN O HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; DOXORUBICIN; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; TELBIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BIOCHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; EVALUATION; FEMALE; HAZARD RATIO; HEPATITIS B; HEPATITIS B VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER HEMORRHAGE; LIVER NECROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NECROINFLAMMATION; OUTCOME ASSESSMENT; PORTAL VEIN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK; VARIX BLEEDING; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; DNA, VIRAL; DROSOPHILA PROTEINS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 70349509880     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.05.025     Document Type: Article

References (35)

1. Chan H.L., and Sung J.J. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 26 (2006) 153-161
2. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
3. Sung J.J., Tsoi K.K., Wong V.W., et al. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 28 (2008) 1067-1077
4. Lai C.L., Chien R.N., Leung N.W., et al. A one-year trial of lamivudine for chronic hepatitis B: Asia Hepatitis Lamivudine Study Group. N Engl J Med 339 (1998) 61-68
5. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
6. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
7. Chang T.T., Gish R.G., de Man R., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
8. Lai C.L., Gane E., Liaw Y.F., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
9. Sorrell M.F., Belongia E.A., Costa J., et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med (2009) 104-110
10. Shamliyan T.A., Macdonald R., Shaukat A., et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med (2009) 111-124
11. Chan H.L., Wong V.W., Chim A.M., et al. Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antivir Ther 12 (2007) 815-823
12. Chan H.L., Wang H., Niu J., et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 12 (2007) 345-353
13. Chan H.L., Leung N.W., Hui A.Y., et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 142 (2005) 240-250
14. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-10
15. Chan H.L., Chui A.K., Lau W.Y., et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 68 (2002) 182-187
16. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
17. Mallet V., Gilgenkrantz H., Serpaggi J., et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 149 (2008) 399-403
18. Fattovich G., Giustina G., Realdi G., et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa: European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 26 (1997) 1338-1342
19. Ikeda K., Saitoh S., Suzuki Y., et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 82 (1998) 827-835
20. Papatheodoridis G.V., Manesis E., and Hadziyannis S.J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 34 (2001) 306-313
21. Lampertico P., Del Ninno E., Vigano M., et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 37 (2003) 756-763
22. van Zonneveld M., Honkoop P., Hansen B.E., et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39 (2004) 804-810
23. Di Marco V., Marzano A., Lampertico P., et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40 (2004) 883-891
24. Lin S.M., Yu M.L., Lee C.M., et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46 (2007) 45-52
25. Hui C.K., Leung N., Shek W.H., et al. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications. J Clin Gastroenterol 42 (2008) 533-538
26. Dienstag J.L., Goldin R.D., Heathcote E.J., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
27. Kim W.R., Flamm S.L., Di Bisceglie A.M., et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47 (2008) 1363-1370
28. Wong V.W., Wong G.L., Tsang S.W., et al. Metabolic and histological features of nonalcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther 29 (2009) 387-396
29. Wong G.L., Wong V.W., Choi P.C., et al. Evaluation of alanine transaminase and hepatitis B virus DNA to predict liver cirrhosis in hepatitis B e antigen-negative chronic hepatitis B using transient elastography. Am J Gastroenterol 103 (2008) 3071-3081
30. Yuen M.F., Yuan H.J., Wong D.K., et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54 (2005) 1610-1614
31. Kim H.C., Nam C.M., Jee S.H., et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 328 (2004) 983
32. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
33. Chan H.L., Tse C.H., Mo F., et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 26 (2008) 177-182
34. Wong V.W., Wong G.L., Tsang S.W., et al. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Antivir Ther 13 (2008) 571-579
35. Chan H.L. Revisiting the treatment recommendations for chronic hepatitis B. Hepatology 49 (2009) 700 author reply 701-702